《渤健Biogen（BIIB）2025年第三季度财务业绩和业务更新报告「NASDAQ」（英文版）（36页）.pdf》由会员分享，可在线阅读，更多相关《渤健Biogen（BIIB）2025年第三季度财务业绩和业务更新报告「NASDAQ」（英文版）（36页）.pdf（36页珍藏版）》请在三个皮匠报告上搜索。

1、THIRD QUARTER 2025 THIRD QUARTER 2025 FINANCIAL RESULTS AND BUSINESS UPDATEFINANCIAL RESULTS AND BUSINESS UPDATEOctober 30,2025This presentation and discussions during this conference call contain forward-looking statements,relating to:our strategy and plans;potential of,and expectations for,our com

2、mercial business and pipeline programs;capitalallocation and investment strategy;clinical development programs,clinical trials,and data readouts and presentations;regulatory discussions,submissions,filings,and approvals;the potential benefits,safety,and efficacy of our andour collaboration partners

3、products and investigational therapies;the anticipated benefits and potential of investments or acquisitions;optimization of our cost structure including our Fit for Growth program;the goal of creatinglong-term sustainable growth;the impact from potential tariffs;productivity of our R&D pipeline,col

4、laborations,and business development activities;our future financial and operating results;and our full year 2025 financialguidance.These forward-looking statements may be accompanied by such words as“aim,”“anticipate,”“assume,”“believe,”“contemplate,”“continue,”“could,”“estimate,”“expect,”“forecast

5、,”“goal,”“guidance,”“hope,”“intend,”“may,”“objective,”“outlook,”“plan,”“possible,”“potential,”“predict,”“project,”“prospect,”“should,”“target,”“will,”“would,”and other words and terms of similar meaning.Drug development and commercialization involve a highdegree of risk,and only a small number of re

6、search and development programs result in commercialization of a product.Results in early-stage clinical trials may not be indicative of full results or results from later stage or largerscale clinical trials and do not ensure regulatory approval.You should not place undue reliance on these statemen